Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mesa Biotech Inc. is active in the Chemistry & Materials technology area with 2 pending office actions. These matters are distributed across 2 distinct examiners and 2 distinct art units. This spread indicates that the patent applications involve different chemical or material classifications requiring specialized review from multiple office divisions. This diversification can be beneficial as it prevents the entire portfolio from being subject to the interpretation of a single examiner or a single art unit's specific policies.
The busiest examiner for the portfolio is KWAK, DEAN P, who is currently handling 1 busiest_examiner_pending action. With 2 pending office actions split between 2 distinct examiners, the company faces a diversified examination environment where each application is being evaluated independently. For a practitioner, this requires a flexible strategy that can adapt to the different technical standards of 2 distinct art units. The presence of multiple examiners means that the overall success is not tied to a single individual's perspective on the chemistry-related innovations, providing a broader base for the company's intellectual property development.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWAK, DEAN P | 1 | 58.9% | +36.7% |
| MUMMERT, STEPHANIE KANE | 1 | 61.4% | +21.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18338392 | Fluidic Test Cassette | KWAK, DEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17696027 | Oscillating Amplification Reaction For Nucleic Acids | MUMMERT, STEPHANIE KANE | 34d |
| 18338392 | Fluidic Test Cassette | KWAK, DEAN P | — |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18338392 | Fluidic Test Cassette | KWAK, DEAN P | 1798 | §102§103§112 | Final Rejection | — | Pending | Jun 21, 2023 |
| 17696027 | Oscillating Amplification Reaction For Nucleic Acids | MUMMERT, STEPHANIE KANE | 1681 | §103Other | Non-Final OA | 34d | Pending | Mar 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMesa Biotech Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Dean P Kwak has the most, with 1 of Mesa Biotech Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.